Physician profile
Tobi Klar
NPI 1609934264
$4,111.67
in general payments reported to CMS, 2019-2025
22 companies · $1,540 in 2025
The $1,540 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $33.25 · 2021: $108 · 2022: $248 · 2023: $812 · 2024: $1,269 · 2025: $1,540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,371 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,371.16 |
| Education | $249.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $791.51 | 2019-2025 | Tremfya, Stelara |
| Lilly USA, LLC | $487.65 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Dermavant Sciences, INC. | $340.40 | 2023-2024 | Vtama |
| Incyte Corporation | $299.31 | 2024-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $297.08 | 2019-2025 | Dupixent |
| Pfizer INC. | $290.21 | 2022-2025 | |
| Botanix Sb INC | $282.64 | 2025 | Sofdra |
| Genzyme Corporation | $257.63 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $218.46 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $206.72 | 2023-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $139.34 | 2023-2024 | Epsolay, Aklief, Twyneo |
| Abbvie INC. | $120.85 | 2021-2024 | |
| Ucb, INC. | $104.86 | 2023-2025 | Bimzelx |
| Amgen INC. | $74.70 | 2024-2025 | Otezla, Otezla |
| Leo Pharma INC. | $34.73 | 2025 | Anzupgo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $31.81 | 2019 | |
| Epi Health, LLC | $25.47 | 2019 | |
| Novo Nordisk INC | $24.05 | 2021 | |
| Organon LLC | $23.58 | 2025 | |
| Grifols USA, LLC | $23.58 | 2023 | Xembify |
| Helsinn Therapeutics (U.S.), INC. | $19.84 | 2022 | |
| Arcutis Biotherapeutics, INC. | $17.25 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tobi Klar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.